A-Alpha Bio and Lawrence Livermore National Laboratory collaborate to accelerate therapeutic antibody discovery against emerging COVID-19 variants
We are very excited to announce our collaboration with Lawrence Livermore National Laboratory to accelerate antibody discovery for emerging COVID-19 variants by training machine learning models with binding data from AlphaSeq.
Supported by the DoD, we will measure millions of protein-protein interactions and train machine learning models to better understand and predict how antibodies bind to coronavirus proteins from COVID-19 variants. These ML models, fueled by LLNL’s powerful computational capabilities, will provide a valuable tool to accelerate the development of coronavirus treatments and will serve as a model for other rapidly evolving infectious diseases and other biothreats. This high-impact work beautifully combines state-of-the-art experimentation and computation – and we are thrilled to be working with the incredibly talented Lawrence Livermore team.
Coverage in NextGov can be read here.